427 related articles for article (PubMed ID: 32545945)
1. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
D'Urso DF; Chiricozzi A; Pirro F; Calabrese L; Caldarola G; Fossati B; De Simone C; Peris K
G Ital Dermatol Venereol; 2020 Aug; 155(4):411-420. PubMed ID: 32545945
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
3. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.
Furtunescu AR; Georgescu SR; Tampa M; Matei C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731900
[TBL] [Abstract][Full Text] [Related]
6. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
7. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
8. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
9. Comparing available JAK inhibitors for treating patients with psoriasis.
Funk PJ; Perche PO; Singh R; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):281-294. PubMed ID: 35129030
[TBL] [Abstract][Full Text] [Related]
10. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
12. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
Kirkham BW; Kavanaugh A; Reich K
Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
15. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
17. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibitors in psoriasis: a promising new treatment modality.
Kwatra SG; Dabade TS; Gustafson CJ; Feldman SR
J Drugs Dermatol; 2012 Aug; 11(8):913-8. PubMed ID: 22859235
[TBL] [Abstract][Full Text] [Related]
20. Updated therapies for the management of Psoriatic Arthritis.
Toussi A; Maverakis N; Le ST; Sarkar S; Raychaudhuri SK; Raychaudhuri SP
Clin Immunol; 2020 Nov; 220():108536. PubMed ID: 32681979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
